Preservation of metabolic flexibility by acetylcarnitine formation

Preservation of metabolic flexibility by acetylcarnitine formation - acetylcarnitine and metabolic flexibility

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON41675

Enrollment

Registered

2013-11-27

Start date

2014-04-22

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-insulin dependant diabetes type 2 diabetes mellitus

Interventions

carnitine/placebo supplementation with 2g carnitine per day (three times daily

1 capsule of 500mg at breakfast, 1 capsul of 500mg at lunch, 2 capsules of 500mg at diner)

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Body mass index (BMI): 25-35, age: 40-70, Hb value > 7.8mmol/l, generally healthy (no medication use that interferes with metabolic parameters under investigation)

Exclusion criteria

Exclusion criteria: contra-indication voor MRI, anemia, plasma creatinine conc > 115micromol/l (men) and > 100 micromol/l (women), high blood pressure (>140 mm Hg (systolic) or >90 (diastolic)), fasting plasma glucose > 7,0 mmol/L

Design outcomes

Primary

Measure	Time frame
metabolic flexibility insulin sensitivity maximal acetyl carnitine formation activity of enzyme carnitine acyl transferase (CrAT)	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)